{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T17:58:13Z","timestamp":1778954293151,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-79942-7","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T13:00:36Z","timestamp":1732194036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identification of inflammation related gene signatures for bladder cancer prognosis prediction"],"prefix":"10.1038","volume":"14","author":[{"given":"Yonggui","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erhao","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"issue":"2","key":"79942_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","volume":"84","author":"I Jubber","year":"2023","unstructured":"Jubber, I. et al. Epidemiology of bladder Cancer in 2023: A systematic review of risk factors. Eur. Urol. 84 (2), 176\u2013190 (2023).","journal-title":"Eur. Urol."},{"key":"79942_CR2","doi-asserted-by":"crossref","unstructured":"Lv, J. et al. HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1\/PKM2 pathway. J. Experimental Clin. Cancer Res. ;42(1). (2023).","DOI":"10.1186\/s13046-023-02614-3"},{"issue":"6","key":"79942_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68 (6), 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"79942_CR4","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay, J. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 136 (5), E359\u2013E86 (2015).","journal-title":"Int. J. Cancer"},{"key":"79942_CR5","doi-asserted-by":"publisher","first-page":"986359","DOI":"10.3389\/fimmu.2022.986359","volume":"13","author":"H Chen","year":"2022","unstructured":"Chen, H. et al. Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer. Front. Immunol. 13, 986359 (2022).","journal-title":"Front. Immunol."},{"issue":"19","key":"79942_CR6","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis, A. T. et al. Bladder cancer: A review. JAMA ;324(19):1980\u20131991. (2020).","journal-title":"JAMA"},{"issue":"3","key":"79942_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.20.01665","volume":"39","author":"JWF Catto","year":"2021","unstructured":"Catto, J. W. F. et al. Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study. J. Clin. Oncol. 39 (3), 202\u2013214 (2021).","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"79942_CR8","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0022-5347(01)66042-7","volume":"155","author":"PU Malmstr\u00f6m","year":"1996","unstructured":"Malmstr\u00f6m, P. U. et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative bladder Cancer Study Group. J. Urol. 155 (6), 1903\u20131906 (1996).","journal-title":"J. Urol."},{"key":"79942_CR9","doi-asserted-by":"publisher","first-page":"1198878","DOI":"10.3389\/fimmu.2023.1198878","volume":"14","author":"H Chen","year":"2023","unstructured":"Chen, H. et al. Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients. Front. Immunol. 14, 1198878 (2023).","journal-title":"Front. Immunol."},{"issue":"5","key":"79942_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/bju.13345","volume":"117","author":"D Ramirez","year":"2016","unstructured":"Ramirez, D. et al. Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer. BJU Int. 117 (5), 783\u2013786 (2016).","journal-title":"BJU Int."},{"issue":"7203","key":"79942_CR11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani, A. et al. Cancer-related inflammation. Nature. 454 (7203), 436\u2013444 (2008).","journal-title":"Nature"},{"key":"79942_CR12","doi-asserted-by":"publisher","first-page":"1126897","DOI":"10.3389\/fonc.2023.1126897","volume":"13","author":"Z Deng","year":"2023","unstructured":"Deng, Z. et al. Inflammation-related research within the field of bladder cancer: A bibliometric analysis. Front. Oncol. 13, 1126897 (2023).","journal-title":"Front. Oncol."},{"issue":"11","key":"79942_CR13","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrc3611","volume":"13","author":"E Elinav","year":"2013","unstructured":"Elinav, E. et al. Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer. 13 (11), 759\u2013771 (2013).","journal-title":"Nat. Rev. Cancer"},{"issue":"21","key":"79942_CR14","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1056\/NEJMoa067208","volume":"356","author":"AT Chan","year":"2007","unstructured":"Chan, A. T., Ogino, S. & Fuchs, C. S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl. J. Med. 356 (21), 2131\u20132142 (2007).","journal-title":"N Engl. J. Med."},{"issue":"2 Suppl 7","key":"79942_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1053\/j.seminoncol.2004.03.041","volume":"31","author":"C-H Koehne","year":"2004","unstructured":"Koehne, C-H. & Dubois, R. N. COX-2 inhibition and colorectal cancer. Semin Oncol. 31 (2 Suppl 7), 12\u201321 (2004).","journal-title":"Semin Oncol."},{"key":"79942_CR16","doi-asserted-by":"publisher","first-page":"115015","DOI":"10.1016\/j.biopha.2023.115015","volume":"164","author":"M Nigam","year":"2023","unstructured":"Nigam, M. et al. Evaluation of the association of chronic inflammation and cancer: Insights and implications. Biomed. Pharmacother. 164, 115015 (2023).","journal-title":"Biomed. Pharmacother"},{"issue":"1","key":"79942_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13046-023-02609-0","volume":"42","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway. J. Exp. Clin. Cancer Res. 42 (1), 38 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"79942_CR18","doi-asserted-by":"publisher","first-page":"972558","DOI":"10.3389\/fonc.2023.972558","volume":"13","author":"X Xiong","year":"2023","unstructured":"Xiong, X. et al. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer. Front. Oncol. 13, 972558 (2023).","journal-title":"Front. Oncol."},{"issue":"6","key":"79942_CR19","doi-asserted-by":"publisher","first-page":"7019","DOI":"10.1002\/cam4.5501","volume":"12","author":"L Ding","year":"2023","unstructured":"Ding, L. et al. Preoperative systemic immune-inflammation index as a significant prognostic factor after TURBT in patients with non-muscle-invasive bladder cancer: a retrospective study based on propensity score matching analysis. Cancer Med. 12 (6), 7019\u20137028 (2023).","journal-title":"Cancer Med."},{"key":"79942_CR20","doi-asserted-by":"crossref","unstructured":"Claps, F. et al. Prognostic value of preoperative albumin-to-fibrinogen ratio (AFR) in patients with bladder cancer treated with radical cystectomy. Urol. Oncol. ;39(12). (2021).","DOI":"10.1016\/j.urolonc.2021.04.026"},{"key":"79942_CR21","doi-asserted-by":"crossref","unstructured":"Claps, F. et al. Impact of the controlling nutritional status (CONUT) score on perioperative morbidity and oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urol Oncol. ;41(1):49.e13-49.e22. (2023).","DOI":"10.1016\/j.urolonc.2022.09.023"},{"issue":"4","key":"79942_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000477405","volume":"93","author":"M Miyake","year":"2017","unstructured":"Miyake, M. et al. Integrative assessment of pretreatment inflammation-, nutrition-, and muscle-based prognostic markers in patients with muscle-invasive bladder cancer undergoing radical cystectomy. Oncology. 93 (4), 259\u2013269 (2017).","journal-title":"Oncology"},{"key":"79942_CR23","doi-asserted-by":"crossref","unstructured":"Schuettfort, V. M., Andrea, D. & Quhal, D. F, et al. Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Urol. Oncol. ;39(4). (2021).","DOI":"10.1016\/j.urolonc.2020.11.005"},{"issue":"8","key":"79942_CR24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.urolonc.2021.03.005","volume":"39","author":"E Laukhtina","year":"2021","unstructured":"Laukhtina, E. et al. Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review. Urol. Oncol. 39 (8), 471\u2013479 (2021).","journal-title":"Urol. Oncol."},{"issue":"3","key":"79942_CR25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.urolonc.2021.10.010","volume":"40","author":"LS Mertens","year":"2022","unstructured":"Mertens, L. S. et al. Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: A multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. Urol. Oncol. 40 (3), 110.e1\u2013e9 (2022).","journal-title":"Urol. Oncol."},{"issue":"6","key":"79942_CR26","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.euo.2021.04.004","volume":"5","author":"MC Mir","year":"2022","unstructured":"Mir, M. C. et al. Adjuvant systemic therapy for high-risk muscle-invasive bladder cancer after radical cystectomy: Current options and future opportunities. Eur. Urol. Oncol. 5 (6), 726\u2013731 (2022).","journal-title":"Eur. Urol. Oncol."},{"issue":"4","key":"79942_CR27","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.euo.2018.05.010","volume":"1","author":"SP Psutka","year":"2018","unstructured":"Psutka, S. P. et al. Staging the host: Personalizing risk assessment for radical cystectomy patients. Eur. Urol. Oncol. 1 (4), 292\u2013304 (2018).","journal-title":"Eur. Urol. Oncol."},{"issue":"18","key":"79942_CR28","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1158\/0008-5472.CAN-04-1916","volume":"64","author":"DM Berman","year":"2004","unstructured":"Berman, D. M. et al. A functional polymorphism in RGS6 modulates the risk of bladder cancer. Cancer Res. 64 (18), 6820\u20136826 (2004).","journal-title":"Cancer Res."},{"key":"79942_CR29","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1146\/annurev.biochem.69.1.795","volume":"69","author":"EM Ross","year":"2000","unstructured":"Ross, E. M. & Wilkie, T. M. GTPase-activating proteins for heterotrimeric G proteins: Regulators of G protein signaling (RGS) and RGS-like proteins. Annu. Rev. Biochem. 69, 795\u2013827 (2000).","journal-title":"Annu. Rev. Biochem."},{"issue":"3","key":"79942_CR30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1124\/pr.54.3.527","volume":"54","author":"S Hollinger","year":"2002","unstructured":"Hollinger, S. & Hepler, J. R. Cellular regulation of RGS proteins: Modulators and integrators of G protein signaling. Pharmacol. Rev. 54 (3), 527\u2013559 (2002).","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"79942_CR31","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/febs.13116","volume":"282","author":"L Ying","year":"2015","unstructured":"Ying, L. et al. Epigenetic repression of regulator of G-protein signaling 2 by ubiquitin-like with PHD and ring-finger domain 1 promotes bladder cancer progression. FEBS J. 282 (1), 174\u2013182 (2015).","journal-title":"FEBS J."},{"issue":"5","key":"79942_CR32","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1111\/cas.14810","volume":"112","author":"M Deng","year":"2021","unstructured":"Deng, M. et al. ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21. Cancer Sci. 112 (5), 1758\u20131771 (2021).","journal-title":"Cancer Sci."},{"issue":"11","key":"79942_CR33","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/kjm2.12588","volume":"38","author":"XH Xu","year":"2022","unstructured":"Xu, X. H. et al. MicroRNA-494-3p facilitates the progression of bladder cancer by mediating the KLF9\/RGS2 axis. Kaohsiung J. Med. Sci. 38 (11), 1070\u20131079 (2022).","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"11","key":"79942_CR34","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/hmg\/6.11.1907","volume":"6","author":"L Lefebvre","year":"1997","unstructured":"Lefebvre, L. et al. Genomic structure and parent-of-origin-specific methylation of Peg1. Hum. Mol. Genet. 6 (11), 1907\u20131915 (1997).","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"79942_CR35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/path.4756","volume":"240","author":"A Boot","year":"2016","unstructured":"Boot, A. et al. Imprinted survival genes preclude loss of heterozygosity of chromosome 7 in cancer cells. J. Pathol. 240 (1), 72\u201383 (2016).","journal-title":"J. Pathol."},{"issue":"2","key":"79942_CR36","first-page":"317","volume":"17","author":"S Nishihara","year":"2000","unstructured":"Nishihara, S. et al. Multipoint imprinting analysis in sporadic colorectal cancers with and without microsatellite instability. Int. J. Oncol. 17 (2), 317\u2013322 (2000).","journal-title":"Int. J. Oncol."},{"issue":"4","key":"79942_CR37","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/mc.1053","volume":"31","author":"M Kohda","year":"2001","unstructured":"Kohda, M. et al. Frequent loss of imprinting of IGF2 and MEST in lung adenocarcinoma. Mol. Carcinog. 31 (4), 184\u2013191 (2001).","journal-title":"Mol. Carcinog."},{"issue":"10","key":"79942_CR38","doi-asserted-by":"publisher","first-page":"6178","DOI":"10.21037\/tcr-20-1006","volume":"9","author":"C Zhao","year":"2020","unstructured":"Zhao, C. et al. MEST promotes bladder cancer cell proliferation, migration and invasion via STAT3\/Twist-1-mediated EMT. Transl Cancer Res. 9 (10), 6178\u20136188 (2020).","journal-title":"Transl Cancer Res."},{"issue":"11","key":"79942_CR39","doi-asserted-by":"publisher","first-page":"e11343","DOI":"10.1016\/j.heliyon.2022.e11343","volume":"8","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. A novel 17 apoptosis-related genes signature could predict overall survival for bladder cancer and its associations with immune infiltration. Heliyon. 8 (11), e11343 (2022).","journal-title":"Heliyon"},{"issue":"1","key":"79942_CR40","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12967-022-03508-2","volume":"20","author":"Q Song","year":"2022","unstructured":"Song, Q. et al. Bladder cancer-derived exosomal KRT6B promotes invasion and metastasis by inducing EMT and regulating the immune microenvironment. J. Transl Med. 20 (1), 308 (2022).","journal-title":"J. Transl Med."},{"issue":"1","key":"79942_CR41","doi-asserted-by":"publisher","first-page":"7425","DOI":"10.1038\/s41598-019-43641-5","volume":"9","author":"Y-R Liu","year":"2019","unstructured":"Liu, Y-R. et al. Enhanced metastatic potential in the MB49 urothelial carcinoma model. Sci. Rep. 9 (1), 7425 (2019).","journal-title":"Sci. Rep."},{"key":"79942_CR42","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.taap.2019.04.021","volume":"374","author":"ZE Hoggarth","year":"2019","unstructured":"Hoggarth, Z. E. et al. Enrichment of genes associated with squamous differentiation in cancer initiating cells isolated from urothelial cells transformed by the environmental toxicant arsenite. Toxicol. Appl. Pharmacol. 374, 41\u201352 (2019).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"79942_CR43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ctrv.2016.03.005","volume":"45","author":"F Massari","year":"2016","unstructured":"Massari, F. et al. Metabolic phenotype of bladder cancer. Cancer Treat. Rev. 45, 46\u201357 (2016).","journal-title":"Cancer Treat. Rev."},{"key":"79942_CR44","doi-asserted-by":"publisher","first-page":"1122570","DOI":"10.3389\/fimmu.2023.1122570","volume":"14","author":"Y Dong","year":"2023","unstructured":"Dong, Y. et al. Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and in vitro validation. Front. Immunol. 14, 1122570 (2023).","journal-title":"Front. Immunol."},{"key":"79942_CR45","doi-asserted-by":"publisher","first-page":"836939","DOI":"10.3389\/fimmu.2022.836939","volume":"13","author":"Q Xiong","year":"2022","unstructured":"Xiong, Q. et al. Fatty acid synthase is the key regulator of fatty acid metabolism and is related to immunotherapy in bladder Cancer. Front. Immunol. 13, 836939 (2022).","journal-title":"Front. Immunol."},{"issue":"1","key":"79942_CR46","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1186\/s12885-021-09006-w","volume":"21","author":"X Li","year":"2021","unstructured":"Li, X. et al. Identification of a novel metabolism-related gene signature associated with the survival of bladder cancer. BMC Cancer. 21 (1), 1267 (2021).","journal-title":"BMC Cancer"},{"issue":"1","key":"79942_CR47","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41392-021-00493-8","volume":"6","author":"J Deng","year":"2021","unstructured":"Deng, J. et al. Metformin targets clusterin to control lipogenesis and inhibit the growth of bladder cancer cells through SREBP-1c\/FASN axis. Signal. Transduct. Target. Ther. 6 (1), 98 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"24","key":"79942_CR48","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-15-0126","volume":"21","author":"SF Jones","year":"2015","unstructured":"Jones, S. F. & Infante, J. R. Molecular pathways: Fatty acid synthase. Clin. Cancer Res. 21 (24), 5434\u20135438 (2015).","journal-title":"Clin. Cancer Res."},{"issue":"1 Pt 2","key":"79942_CR49","first-page":"R146","volume":"247","author":"M Ookhtens","year":"1984","unstructured":"Ookhtens, M. et al. Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am. J. Physiol. 247 (1 Pt 2), R146\u2013R53 (1984).","journal-title":"Am. J. Physiol."},{"issue":"1","key":"79942_CR50","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12032-014-0391-z","volume":"32","author":"Y Cai","year":"2015","unstructured":"Cai, Y. et al. Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer. Med. Oncol. 32 (1), 391 (2015).","journal-title":"Med. Oncol."},{"issue":"9","key":"79942_CR51","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1158\/1055-9965.EPI-09-0144","volume":"18","author":"K Walter","year":"2009","unstructured":"Walter, K. et al. Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol. Biomarkers Prev. 18 (9), 2380\u20132385 (2009).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"10","key":"79942_CR52","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.1210\/jc.2008-0503","volume":"93","author":"S Uddin","year":"2008","unstructured":"Uddin, S. et al. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J. Clin. Endocrinol. Metab. 93 (10), 4088\u20134097 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"79942_CR53","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1038\/s41418-021-00768-1","volume":"28","author":"M Humbert","year":"2021","unstructured":"Humbert, M. et al. Reducing FASN expression sensitizes acute myeloid leukemia cells to differentiation therapy. Cell. Death Differ. 28 (8), 2465\u20132481 (2021).","journal-title":"Cell. Death Differ."},{"issue":"2","key":"79942_CR54","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10549-021-06231-6","volume":"187","author":"A Gruslova","year":"2021","unstructured":"Gruslova, A. et al. FASN inhibition as a potential treatment for endocrine-resistant breast cancer. Breast Cancer Res. Treat. 187 (2), 375\u2013386 (2021).","journal-title":"Breast Cancer Res. Treat."},{"issue":"14","key":"79942_CR55","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.7150\/ijbs.45640","volume":"16","author":"M Shahid","year":"2020","unstructured":"Shahid, M. et al. S-palmitoylation as a functional regulator of proteins associated with cisplatin resistance in bladder cancer. Int. J. Biol. Sci. 16 (14), 2490\u20132505 (2020).","journal-title":"Int. J. Biol. Sci."},{"issue":"3","key":"79942_CR56","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1002\/jcp.27129","volume":"234","author":"T Tao","year":"2019","unstructured":"Tao, T. et al. Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT\/mTOR\/SREBP-1c axis. J. Cell. Physiol. 234 (3), 3088\u20133104 (2019).","journal-title":"J. Cell. Physiol."},{"key":"79942_CR57","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.anndiagpath.2019.01.002","volume":"39","author":"AE Abdelrahman","year":"2019","unstructured":"Abdelrahman, A. E. et al. Fatty acid synthase, Her2\/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer. Ann. Diagn. Pathol. 39, 42\u201352 (2019).","journal-title":"Ann. Diagn. Pathol."},{"key":"79942_CR58","doi-asserted-by":"crossref","unstructured":"Barone, B. et al. Preoperative fibrinogen-to-albumin ratio as potential predictor of bladder cancer: A monocentric retrospective study. Med. (Kaunas) ;58(10). (2022).","DOI":"10.3390\/medicina58101490"},{"key":"79942_CR59","doi-asserted-by":"crossref","unstructured":"Crocetto, F. et al. A comparative study of the Triglycerides\/HDL ratio and pseudocholinesterase levels in patients with bladder Cancer. Diagnostics (Basel) ;12(2). (2022).","DOI":"10.3390\/diagnostics12020431"},{"issue":"2","key":"79942_CR60","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/bju.15984","volume":"132","author":"F Claps","year":"2023","unstructured":"Claps, F. et al. Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy. BJU Int. 132 (2), 170\u2013180 (2023).","journal-title":"BJU Int."},{"issue":"4","key":"79942_CR61","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","volume":"77","author":"A Necchi","year":"2020","unstructured":"Necchi, A. et al. Updated results of PURE-01 with preliminary activity of Neoadjuvant Pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur. Urol. 77 (4), 439\u2013446 (2020).","journal-title":"Eur. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79942-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79942-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79942-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T14:05:34Z","timestamp":1732197934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79942-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["79942"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79942-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"24 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28867"}}